Drugs / CAR-CLD18 T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03159819 | Apr 2017 → Dec 2019 | gastric adenocarcinoma, pancreatic adenocarcinoma | Changhai Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-CLD18 T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03159819 ↗ |
| Modality | Cell therapy | “Autologous T Cells with a Claudin18.2-redirected Chimeric Antigen Receptor.” NCT03159819 ↗ |
| Route | Intravenous | “Route of administration: Intravenous injection.” NCT03159819 ↗ |